20 articles
A first-in-human Phase 1 trial evaluates PF-07257876, a dual-checkpoint bispecific antibody targeting both CD47 and PD-L1, in hard-to-treat cancers.
A newly discovered hepatic micropeptide suppresses liver cancer progression by jamming a key mitochondrial RNA processing complex.
Ketogenic diet metabolite enhances CAR T cell metabolism and tumor control in multiple cancer models
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
Stanford scientists used RFdiffusion and ProteinMPNN to build a compact ฮฑ-helical TCR mimic with 9.5 nM affinity for a tumor antigen โ and near-perfect peptide specificity.
Pfizer's first-in-human trial of PF-07209960, a dual-action immunotherapy fusion protein, was terminated after enrolling 37 patients.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.
BCG therapy for bladder cancer travels to bone marrow, reprogramming stem cells to produce enhanced immune cells that fight tumors throughout the body.
A new machine learning tool called MaNeo scans tumor peptides to identify neoantigens that activate T cells against cancer while sparing healthy cells.
Phase 1 trial shows MP0317 activates anti-tumor immunity in solid tumors with a favorable safety profile, supporting combination therapy.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
B7-H3-targeted therapy HS-20093 achieved 52% response rate in small cell lung cancer and 22% in non-small cell lung cancer patients.
New study shows circulating tumor cells can predict treatment response and reveal drug resistance patterns.
Researchers develop monoclonal antibody that specifically inhibits heparanase, reducing tumor growth and metastasis in multiple cancer types.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
A Phase 2 trial testing AR blockade combined with PD-1 inhibition in treatment-emergent neuroendocrine prostate cancer was terminated early.
Novel nanoparticle combines protein degrader with light therapy to reprogram cancer metabolism and eliminate breast tumors.
Scientists discover ALPK1 receptor agonists trigger powerful anti-tumor immunity, offering new immunotherapy approach beyond current treatments.
A 260-organoid biobank reveals statins target chemoresistant pancreatic cancer by disrupting cholesterol and glycosylation pathways.
